A recent hearing on health cost transparency in the House Energy & Commerce/Health Subcommittee nicely captured the two extremes in play during the current Congressional efforts to further address drug pricing in the US.
The broadly focused hearing looked at new fewer than 17 different bills that would touch on essentially all aspects of the fragmented US system, with provisions ranging from efforts to...